cxcr5  (Cell Signaling Technology Inc)

Journal: Frontiers in Immunology

Article Title: High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+ T-cell infiltration in gastric cancer

doi: 10.3389/fimmu.2025.1551259

Figure Lengend Snippet: (A) Kaplan-Meier survival curves for PFS (top) and OS (bottom) in cohort 1, comparing patients with simultaneous high expression of CXCR5 and CD8 (CXCR5 H CD8 H ) to other expression groups ( n = 89; log-rank test, p -values shown). (B) Representative IF staining of responders and non-responders. Samples were stained for CXCR5 (green), CD8 (red), and DAPI (blue).

Article Snippet: The following primary antibodies were used: CXCL13 (dilution 1:500; Abcam), CD4 (dilution 1:1200; Abcam, USA), CD8 (working solution; Zhongshan Jinqiao, China), CD20 (dilution 1:300; Invitrogen, USA), and CXCR5 (dilution 1:200; CST, USA).

Techniques: Expressing, Staining

Journal: Frontiers in Immunology

Article Title: High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+ T-cell infiltration in gastric cancer

doi: 10.3389/fimmu.2025.1551259

Figure Lengend Snippet: (A) Kaplan–Meier survival curves for PFS and OS according to concurrent high expression of CXCL13, CXCR5, and CD8 (CXCL13 H CXCR5 H CD8 H vs. other expression). (B) Multivariate analysis based on clinicopathological characteristics and the expression of CXCL13, CXCR5, and CD8 in cohort 1 patients. (C) CXCL13, CXCR5, and CD4 (CXCL13 H CXCR5 H CD4 H vs. other expression). (D) Multivariate analysis based on clinicopathological characteristics and the expression of CXCL13, CXCR5, and CD4 in cohort 1 patients (log-rank test for Kaplan–Meier curves. HR, hazard ratio; CI, confidence interval).

Article Snippet: The following primary antibodies were used: CXCL13 (dilution 1:500; Abcam), CD4 (dilution 1:1200; Abcam, USA), CD8 (working solution; Zhongshan Jinqiao, China), CD20 (dilution 1:300; Invitrogen, USA), and CXCR5 (dilution 1:200; CST, USA).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+ T-cell infiltration in gastric cancer

doi: 10.3389/fimmu.2025.1551259

Figure Lengend Snippet: (A) Kaplan–Meier survival curves for PFS (left) and OS (right) in cohort 1 patients stratified by the presence of TLSs. (B) Representative images of TLSs (H&E staining) and expression of CD20, CD8, and CXCR5 within TLSs. (C) Frequencies of CXCR5 H CD8 H and CXCR5 H CD4 H expression were compared to other expression groups, based on TLS presence and CXCL13 expression levels.

Article Snippet: The following primary antibodies were used: CXCL13 (dilution 1:500; Abcam), CD4 (dilution 1:1200; Abcam, USA), CD8 (working solution; Zhongshan Jinqiao, China), CD20 (dilution 1:300; Invitrogen, USA), and CXCR5 (dilution 1:200; CST, USA).

Techniques: Staining, Expressing

Journal: Frontiers in Immunology

Article Title: High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+ T-cell infiltration in gastric cancer

doi: 10.3389/fimmu.2025.1551259

Figure Lengend Snippet: (A) Percentage of CXCR5+CD8+ T cells and (B) PD-1+CD8+ T cells in peripheral blood, subcutaneous tumor, and spleen across the four indicated treatment groups ( n = 5 per group). (C) Percentage of effector cytokines (GZMB, IFN-γ, IL-2, IL-17A, and TNF-α) in peripheral blood across the four indicated groups ( n = 5 per group). (Bar plots represent mean ± SD; ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns, not significant).

Article Snippet: The following primary antibodies were used: CXCL13 (dilution 1:500; Abcam), CD4 (dilution 1:1200; Abcam, USA), CD8 (working solution; Zhongshan Jinqiao, China), CD20 (dilution 1:300; Invitrogen, USA), and CXCR5 (dilution 1:200; CST, USA).

Techniques:

Journal: bioRxiv

Article Title: Multi-modal profiling identifies CD4+CXCR5+PD-1- Tfh cells as prognostic and predictive biomarkers for response to R-CHOP therapy in human DLBCL

doi: 10.1101/2024.10.10.617515

Figure Lengend Snippet: (a) Representative composite images of DLBCL tumor tissues with multiplexed staining and imaging of individual markers (DAPI, blue; CD20, red; CD4, magenta; CD8, cyan; PD-1, yellow; CXCR5, green). Scale bar, 50 μm. (b) Percentage of PD-1 + , CD20 + , CD4 + , CXCR5 + and CD8 + cells in DLBCL patients, statistical significance was determined with the multiple unpaired t test. (c) Representative images of CD4 + CXCR5 + PD-1 - TFH cells in DLBCL tumor. Scale bar, 20 μm. (d) Percentage of CD4 + CXCR5 + PD-1 - TFH cells, statistical significance was determined with the Wilcoxon signed-rank test. (e) Overall survival analysis of CD4 + CXCR5 + PD-1 - TFH cells in tissue samples from DLBCL patients. Patients were divided into two groups based on cell count above and below the median values. Differences between groups were evaluated using a log-rank test. Patients were divided into two groups based on cell count above and below the median values. Difference between groups was evaluated using a log-rank test. (f) Representative pattern (left) and representative proximity distance map (right) showing CD4 + CXCR5 + PD-1 - TFH cells within or outside the radius of 50 μm from the nuclear center of CD20 + tumor cells in the two groups. (g) Average number of CD4 + CXCR5 + PD-1 - TFH cells within 50 μm of CD20 + tumor cells in the two groups, statistical significance was determined with the Wilcoxon signed-rank test. (h) Overall survival analysis with average number of CD4 + CXCR5 + PD-1 - TFH cells within 50 μm of CD20 + tumor cells in tissue samples from DLBCL patients. Patients were divided into two groups, based on cell count above and below the median values. Differences between groups were evaluated using a log-rank test. (i) Representative composite image of the effect of CD4 + CXCR5 + PD-1 - TFH cells on CD20 + tumor cells in DLBCL patients. Scale bar, 20 μm. (j) Number of CD4 + CXCR5 + PD-1 - TFH cells interacting with every single CD20 + tumor cells (< 20 μm) in two groups, statistical significance was determined with the Wilcoxon signed-rank test. (k) Overall survival analysis with number of CD4 + CXCR5 + PD-1 - TFH cells interacting with every single CD20 + tumor cells in tissue samples from DLBCL patients. Patients were divided into two groups, based on cell count above and below the median values. Differences between groups were evaluated using a log-rank test. (l) The scRNA-seq profiles reveal the heterogeneity and cellular mechanisms in relapsed/refractory DLBCL.

Article Snippet: The same process was repeated for the following antibodies/fluorescent dyes, in order: anti-PD-1 (10377-MM23, Sino biological, China)/ TSA 570, anti-CXCR5 (72172s, CST, US)/ TSA 520, anti-CD4 (ab133616, Abcam, US)/TSA 670, anti-CD8(BX50036, Biolynx, China)/ TSA 440.

Techniques: Staining, Imaging, Cell Counting

Journal: bioRxiv

Article Title: Multi-modal profiling identifies CD4+CXCR5+PD-1- Tfh cells as prognostic and predictive biomarkers for response to R-CHOP therapy in human DLBCL

doi: 10.1101/2024.10.10.617515

Figure Lengend Snippet: (a) Schematic diagram of the mIHC image prediction network. The generation network comprises a generator and a discriminator. The generator utilizes a ResNet-6block architecture to produce mIHC images, while the discriminator employs a PatchGAN-based modalities discriminator module. (b) Classification performance for CD4 + TFH1 cells using generated mIHC images. The upper panel displays the confusion matrix for CD4 + TFH1 cell classification across 2000 generated mIHC images. The lower panel presents various classification metrics for CD4 + TFH1 cell identification, including accuracy , recall score , precision , and F1 score . (c) The visualization of image generation results. Here we show three cases. In each column, the top image is the DAPI-stained Image, the middle image is the corresponding mIHC image, and the bottom one is the synthetic mIHC image generated with our proposed method (DAPI, blue; CD20, red; CD4, magenta; CD8, cyan; PD-1, yellow; CXCR5, green), Scale bar, 200 μm.

Article Snippet: The same process was repeated for the following antibodies/fluorescent dyes, in order: anti-PD-1 (10377-MM23, Sino biological, China)/ TSA 570, anti-CXCR5 (72172s, CST, US)/ TSA 520, anti-CD4 (ab133616, Abcam, US)/TSA 670, anti-CD8(BX50036, Biolynx, China)/ TSA 440.

Techniques: Generated, Staining